SCHEMBL7969416

SCHEMBL7969416

CN(CCN(C)C(=O)c1ncc[nH]1)C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
GBA1 P04062 1/20 0.36
PDK2 Q15119 1/20 0.35
CACNA1G O43497 1/20 0.34
CACNA1B Q00975 1/20 0.34
CACNA1C Q13936 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
SSTR4 P31391 1/20 0.34
AAK1 Q2M2I8 3/20 0.34
L3MBTL1 Q9Y468 1/20 0.32
KMT2A Q03164 1/20 0.32
CCNE2 O96020 1/20 0.32
CCNE1 P24864 1/20 0.32
CDK2 P24941 1/20 0.32
HTR2C P28335 1/20 0.31
SLC6A4 P31645 1/20 0.31
BUB1 O43683 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9223865 0.84 NPC1 (0.35) NPC1RAB9AGBA1PDK2CACNA1G
SCHEMBL7969408 0.82 NPC1 (0.35) NPC1RAB9ASSTR4AAK1KMT2A
SCHEMBL10260946 0.74 HDAC6 (0.40) GBA1PDK2CACNA1GCACNA1BCACNA1C
SCHEMBL2429665 0.74 NPC1 (0.45) NPC1RAB9AKMT2A
SCHEMBL2424191 0.72 PAX8 (0.35) NPC1RAB9ACACNA1GCACNA1BCACNA1C
SCHEMBL970408 0.71 NPC1 (0.49) NPC1RAB9AKMT2A
SCHEMBL5838309 0.71 NPC1 (0.42) NPC1RAB9AKMT2A
SCHEMBL22372037 0.71 NPC1 (0.40) NPC1RAB9AHRH4KMT2A
SCHEMBL5164159 0.71 NPC1 (0.40) NPC1RAB9AL3MBTL1KMT2A
SCHEMBL16984510 0.70 SIRT6 (0.40) GBA1PDK2CACNA1GCACNA1BCACNA1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6297241-B1 TREATMENT OF DISORDERS WHICH ARE RESPONSIVE TO THE OPENING OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS. BRISTOL-MYERS SQUIBB COMPANY 2001-10-02 US disclosed